Pelthos Therapeutics Inc. (the Company ) is a bio-pharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens. Food and Drug Administration ( FDA ) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMI TM , XEPI , and XEGLYZE .
The business is unprofitable at the operating level (-193.09% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Negative free cash flow of -$23M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$17M
Net Income (TTM)
-$52M
▼ -444.6% YoY
Op. Margin
-193.09%
ROIC
-70.21%
▲ +1525.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$35M
▼ -291.7% YoY
Op. Cash Flow (TTM)
-$35M
▼ -290.0% YoY
Net Debt
-$5M
Net Cash Position
Cash & Equiv.
$32M
Continue Research